This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Apr 8;464(7290):844-5.

doi: 10.1038/464844a.

Cancer: drug-tolerant insurgents

Paul Workman, Jon Travers

PMID: 20376142
DOI: 10.1038/464844a

Cancer: drug-tolerant insurgents

Paul Workman et al. Nature. 2010.

. 2010 Apr 8;464(7290):844-5.

doi: 10.1038/464844a.

Authors

Paul Workman, Jon Travers

PMID: 20376142
DOI: 10.1038/464844a

No abstract available

PubMed Disclaimer

Similar articles

Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
Mathur G, Ma D. Mathur G, et al. J Thorac Oncol. 2014 Jul;9(7):e55-e57. doi: 10.1097/JTO.0000000000000197. J Thorac Oncol. 2014. PMID: 24926557 No abstract available.
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T. Suda K, et al. J Thorac Oncol. 2011 Jul;6(7):1152-61. doi: 10.1097/JTO.0b013e318216ee52. J Thorac Oncol. 2011. PMID: 21597390
Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
Farhan M, Malik A, Ullah MF, Afaq S, Faisal M, Farooqi AA, Biersack B, Schobert R, Ahmad A. Farhan M, et al. Int J Mol Sci. 2019 Feb 13;20(4):800. doi: 10.3390/ijms20040800. Int J Mol Sci. 2019. PMID: 30781783 Free PMC article.
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K. Nurwidya F, et al. Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30. Respir Investig. 2014. PMID: 24636263 Review.
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Forde PM, Ettinger DS. Forde PM, et al. Clin Adv Hematol Oncol. 2015 Aug;13(8):528-32. Clin Adv Hematol Oncol. 2015. PMID: 26351816 Review.

See all similar articles

Cited by

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.
Thiagarajan PS, Wu X, Zhang W, Shi I, Bagai R, Leahy P, Feng Y, Veigl M, Lindner D, Danielpour D, Yin L, Rosell R, Bivona TG, Zhang Z, Ma PC. Thiagarajan PS, et al. Oncotarget. 2016 Dec 13;7(50):82013-82027. doi: 10.18632/oncotarget.13307. Oncotarget. 2016. PMID: 27852038 Free PMC article.
Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments.
Jekunen AP. Jekunen AP. J Oncol. 2015;2015:809835. doi: 10.1155/2015/809835. Epub 2015 Jan 29. J Oncol. 2015. PMID: 25699082 Free PMC article. Review.
KDM5 Lysine Demethylases in Pathogenesis, from Basic Science Discovery to the Clinic.
Zhang SM, Cao J, Yan Q. Zhang SM, et al. Adv Exp Med Biol. 2023;1433:113-137. doi: 10.1007/978-3-031-38176-8_6. Adv Exp Med Biol. 2023. PMID: 37751138
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, Fu P, Huang H, Bagai R, Jiang S, Kresak A, Howell S, Vasanji A, Flask CA, Halmos B, Koon H, Ma PC. Fan W, et al. Cancer Res. 2011 Jul 1;71(13):4494-505. doi: 10.1158/0008-5472.CAN-10-2668. Epub 2011 May 9. Cancer Res. 2011. PMID: 21555370 Free PMC article.
Envisioning the future of early anticancer drug development.
Yap TA, Sandhu SK, Workman P, de Bono JS. Yap TA, et al. Nat Rev Cancer. 2010 Jul;10(7):514-23. doi: 10.1038/nrc2870. Epub 2010 Jun 10. Nat Rev Cancer. 2010. PMID: 20535131 Review.

See all "Cited by" articles

References

1. Ann Oncol. 2001 Jan;12(1):23-7 - PubMed
1. Cell. 2010 Apr 2;141(1):69-80 - PubMed
1. Nat Med. 2007 Oct;13(10):1144-5 - PubMed
1. Hematology Am Soc Hematol Educ Program. 2009;:3-12 - PubMed
1. Front Biosci. 2008 May 01;13:5138-54 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information